There is a fear that with the series of stories in Bloomberg, additional shoes will fall. A little while back there was a similar issue with another testing outfit (PDII, actually, more of a contract drug marketeer) or something like that) it got punished hard, but when the clouds cleared it came back and bounced a solid 35%. Growth next year may be slower than their torrential recent growth, particularly in view of the shorts attack through the Bloomberg stories. I thin that here ii is selling at less than 8 PE or so, and a PEG under .4. Seems like a deal if they survive.
Market Data 
Markets 
AI
